Abstract
Sequential use of afatinib and osimertinib could be an effective strategy in EGFRm+ NSCLC pts with T790M-mediated resistance to 1st-line treatment. Two recent non-interventional trials, GioTag and UpSwinG, demonstrated encouraging time-to-treatment failure (TTF) and overall survival (OS) in pts receiving sequential afatinib and osimertinib, especially in Asian pts (median TTF: 28.8-37.1 months; median OS: 42.3-44.8 months). Here, in order to increase cohort size and facilitate sub-group analysis, we have undertaken a combined analysis of Asian pts from GioTag and UpSwinG.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call